Insmed Inc (NASDAQ:INSM) on Friday outlined a commercial and clinical roadmap for 2026, highlighting strong momentum from its respiratory portfolio and a series of upcoming trial readouts and launches that could shape the company's growth over the next 18 months. • Insmed stock is gaining positive traction. Why are INSM shares climbing?Speaking ahead of Insmed's presentation at the J.P. Morgan Healthcare Conference, Will Lewis, chair and CEO, said 2025 marked a turning point for the company as it translated ...